PET imaging of prostate cancer
- Author(s)
- Ong, JSL; Hofman, MS;
- Journal Title
- In: Signore, A. (ed) Nuclear Medicine and Molecular Imaging, Volume 3
- Publication Type
- Book section
- Abstract
- Prostate specific membrane antigen positron emission tomography (PSMA PET) has revolutionized imaging in prostate cancer over the last decade. As a disease detection modality, PSMA PET outperforms other PET tracers and conventional imaging modalities in all stages of disease. Accordingly, there has been widespread adoption into clinical practice and recent FDA approvals of PSMA tracers will facilitate improved access for prostate cancer patients. As with any new imaging modality, a detailed understanding of tracer biodistribution, physiological expression and pitfalls is critical for accurate interpretation, as well as the importance of characterizing disease heterogeneity by combining PSMA PET imaging with other tracers. This is especially important in the era of PSMA theranostics, a new class of effective prostate cancer therapy based on PET imaging to guide treatment. This chapter provides an overview of PET imaging in prostate cancer, starting with a synopsis of prostate cancer, the range of molecular imaging targets utilized in PET imaging, details of PSMA imaging including ligand biodistribution, scan performance and interpretation, a summary of the clinical scenarios where PSMA PET has clinical value and future considerations.
- Publisher
- Elsevier
- Keywords
- CRPC; DCFPyL; FDG; HSPC; Lu-PSMA; PET; Prostate; Prostate cancer; PSMA; PSMA-1007; PSMA-11; Theranostics
- Department(s)
- Cancer Imaging
- Publisher's Version
- https://doi.org/10.1016/B978-0-12-822960-6.00111-3
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-02-14 04:06:09
Last Modified: 2025-02-14 04:08:15